The FDA’s database for drug approvals includes an Abbreviated New Drug Application (ANDA) numbered ANDA083639 submitted by Roche. The application covers the brand name ENDEP, an oral tablet formulation of amitriptyline hydrochloride.
The ANDA lists five product variants, each with a distinct strength—10 mg, 25 mg, 50 mg, 75 mg, and 100 mg. All five tablets are designated as “Discontinued” in marketing status, indicating they are no longer marketed.
Actualités réglementaires25 août 2026•1 min de lecture
FDA Lists ENDEP Amitriptyline Tablet Products (ANDA083639)
FDA’s ANDA083639 lists five ENDEP oral amitriptyline tablets (10‑100 mg) from Roche, all marked discontinued.
Compilé par l'équipe PharmaCountry · Source : FDA.gov
Évaluations
(0)
(0)
(0)
(0)
(0)
Plus d'articles
Voir tous les articlesRecherches & Rapports
Global Finished Dosage Manufacturing Landscape 2026
5 oct. 2026
Actualités réglementairesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept. 2026
Laissez votre note